In the life sciences industry, IP is everything. Join us for an in-depth look at IP for life sciences start-ups with Dr. Chris Barden, CEO of US/Canadian pharma company Treventis Corp. and a registered U.S. Patent Agent. Dr. Barden will share “lessons learned” navigating the regulatory system in the U.S. and the EU and how he built a robust IP portfolio. At Treventis he leads a team of scientists working on disease-modifying therapeutics against protein misfolding diseases such as Alzheimer’s (the subject of a $370MM partnership with Takeda).
Topics covered:
- When and when NOT to Patent
- U.S. Clinical Research Regulations
- Protecting Trade Secrets
- Leveraging licensing opportunities
- Tactics and Best Practices
About Dr. Chris Barden
Chris is a serial entrepreneur and inventor (80+ issued patents) with R&D, operating, dealmaking, and other executive experience in several pharmaceutical, medical device, and diagnostic start-ups. At Treventis, he leads a team of scientists working to design disease-modifying therapeutics against protein misfolding diseases such as Alzheimer’s (the subject of a $370MM partnership with Takeda). In his IP consulting practice, Chris brings a founder’s perspective to the complicated landscape of patent rules and regulations, helping companies understand how to best position their IP for commercial success, particularly in the US market. He received his Ph.D. in Physical (Computational) Chemistry from the Schaefer group at University of Georgia.
This interactive workshop is for inventors and entrepreneurs to learn how to protect intellectual property and incorporate a successful IP strategy in the commercialization and monetization of their IP and technologies!
Start-ups can book a 1:1 virtual session with Dr. Barden following the workshop.